X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

XFOR 10.24.2024

Full Press ReleaseSEC FilingsOur XFOR Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
  • 12.04.2024 - X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition
  • 12.03.2024 - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

  • 01.16.2025 - S-8 Securities to be offered to employees in employee benefit plans
  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1

BOSTON,Oct. 24, 2024(GLOBE NEWSWIRE) --X4 Pharmaceuticals, Inc.(Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter endedSeptember 30, 2024and present results from its concluded Phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia onWednesday, November 13, 2024.

The company will host a conference call and webcast on the same day at8:00 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 fromthe United Statesor 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast and accompanying slide presentation will be accessible through the investor relations section of X4 Pharmaceuticals’ website atwww.x4pharma.com. Following the conclusion of the call and webcast, a replay will be available on the company’s website.

AboutX4 PharmaceuticalsX4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has receivedU.S.approval as XOLREMDI®(mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are inBoston, Massachusettsand our research center of excellence is inVienna, Austria. For more information, please visit our website atwww.x4pharma.com.

Company Contact:José JuvesHead of Corporate & Patient Affairsjose.juves@x4pharma.com

Investor Contact:Daniel FerryManaging Director,LifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576

Primary Logo

Source: X4 Pharmaceuticals

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com